Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Masayoshi Harigai, Tsutomu Takeuchi, Josef S. Smolen, Kevin L. Winthrop, Atsushi Nishikawa, Terence P. Rooney, Chadi G. Saifan, Maher Issa, Yoshitaka Isaka, Naotsugu Akashi, Taeko Ishii & Yoshiya Tanaka. (2020) Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. Modern Rheumatology 30:1, pages 36-43.
Read now
Read now
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, Vasiliky Liakouli, Francesco Carubbi, Onorina Berardicurti, Francesco Ciccia, Giuliana Guggino, Giovanni Triolo & Roberto Giacomelli. (2017) Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. Expert Review of Clinical Immunology 13:11, pages 1041-1047.
Read now
Read now
Pablo Olivera, Silvio Danese & Laurent Peyrin-Biroulet. (2017) JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology 13:7, pages 693-703.
Read now
Read now
Angela Mauro, Donato Rigante & Rolando Cimaz. (2017) Investigational drugs for treatment of juvenile idiopathic arthritis. Expert Opinion on Investigational Drugs 26:4, pages 381-387.
Read now
Read now
Shingo Nakayamada, Satoshi Kubo, Shigeru Iwata & Yoshiya Tanaka. (2016) Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy 17:16, pages 2215-2225.
Read now
Read now
Articles from other publishers (26)
Shoaib Khan, Krishna Mohan, Sazina Muzammil, Md. Aftab Alam & Khalid Umer Khayyam. (2024) Current Prospects in Rheumatoid Arthritis: Pathophysiology,
Genetics, and Treatments. Recent Advances in Anti-Infective Drug Discovery 19:1, pages 36-55.
Crossref
Crossref
Ying Qu, Bingyang Chu, Jianan Li, Hanzhi Deng, Ting Niu & Zhiyong Qian. (2023) Macrophage‐Biomimetic Nanoplatform‐Based Therapy for Inflammation‐Associated Diseases. Small Methods.
Crossref
Crossref
Yeganeh Mehrani, Rasool Rahimi Junqani, Solmaz Morovati, Hossein Mehrani, Negar Karimi & Samaneh Ghasemi. (2023) The Importance of Neutrophils in Osteoarthritis: Current Concepts and Therapeutic Perspectives. Immuno 3:3, pages 250-272.
Crossref
Crossref
Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Crossref
Shuyan Wang, Dan Wang, Yaou Duan, Zhidong Zhou, Weiwei Gao & Liangfang Zhang. (2022) Cellular Nanosponges for Biological Neutralization. Advanced Materials 34:13, pages 2107719.
Crossref
Crossref
Nightingale Syabbalo. (2022) The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. Journal of Lung, Pulmonary & Respiratory Research 9:1, pages 17-32.
Crossref
Crossref
Xiaofeng Zeng, Dongbao Zhao, Sebastiao C. Radominski, Mauro Keiserman, Chang K. Lee, Sebastian Meerwein, Jeffrey Enejosa, Yunxia Sui, Mohamed‐Eslam F. Mohamed & Won Park. (2021) Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. International Journal of Rheumatic Diseases 24:12, pages 1530-1539.
Crossref
Crossref
Xiaoyan Chen, Guangsheng Du, Shuting Bai, Liu Dijia, Chenglong Li, Yingying Hou, Yuandong Zhang, Zhirong Zhang, Tao Gong, Yao Fu, Massimo Bottini & Xun Sun. (2021) Restoring immunological tolerance in established experimental arthritis by combinatorial citrullinated peptides and immunomodulatory signals. Nano Today 41, pages 101307.
Crossref
Crossref
Ayesha Rehman, Peter John & Attya Bhatti. (2021) Biogenic Selenium Nanoparticles: Potential Solution to Oxidative Stress Mediated Inflammation in Rheumatoid Arthritis and Associated Complications. Nanomaterials 11:8, pages 2005.
Crossref
Crossref
Maha Saber-Ayad, Sarah Hammoudeh, Eman Abu-Gharbieh, Rifat Hamoudi, Hamadeh Tarazi, Taleb H. Al-Tel & Qutayba Hamid. (2021) Current Status of Baricitinib as a Repurposed Therapy for COVID-19. Pharmaceuticals 14:7, pages 680.
Crossref
Crossref
Jiaxin Li, Yang Long, Rong Guo, Kebai Ren, Zhengze Lu, Man Li, Xuhui Wang, Jiaxin Li, Yashi Wang, Zhirong Zhang & Qin He. (2021) Shield and sword nano-soldiers ameliorate rheumatoid arthritis by multi-stage manipulation of neutrophils. Journal of Controlled Release 335, pages 38-48.
Crossref
Crossref
Erika P. Navarro, Iván Posso-Osorio, David Aguirre-Valencia, Juan Naranjo-Escobar & Gabriel J. Tobón. (2021) Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis. JCR: Journal of Clinical Rheumatology 27:2, pages e58-e60.
Crossref
Crossref
Nobunori Takahashi, Shuji Asai, Tomonori Kobayakawa, Atsushi Kaneko, Tatsuo Watanabe, Takefumi Kato, Tsuyoshi Nishiume, Hisato Ishikawa, Yutaka Yoshioka, Yasuhide Kanayama, Tsuyoshi Watanabe, Yuji Hirano, Masahiro Hanabayashi, Yuichiro Yabe, Yutaka Yokota, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Naoki Ishiguro & Toshihisa Kojima. (2020) Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Scientific Reports 10:1.
Crossref
Crossref
Daisuke Miyatake, Tomohisa Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tetsuya Nishimura, Masataka Katashima, Masashi Sakaki, Kazuaki Inoue, Takayoshi Ito, Naoki Uchida, Kenichi Furihata & Akinori Urae. (2019) Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function. Clinical Pharmacology in Drug Development 9:6, pages 699-708.
Crossref
Crossref
Mark C Genovese, Josef S Smolen, Tsutomu Takeuchi, Gerd Burmester, Dennis Brinker, Terence P Rooney, Jinglin Zhong, Mo Daojun, Chadi Saifan, Anabela Cardoso, Maher Issa, Wen-Shuo Wu & Kevin L Winthrop. (2020) Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. The Lancet Rheumatology 2:6, pages e347-e357.
Crossref
Crossref
Maha Saber-Ayad, Mohamed A. Saleh & Eman Abu-Gharbieh. (2020) The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 13:5, pages 96.
Crossref
Crossref
Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei & Shiqin Sun. (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology 80, pages 106210.
Crossref
Crossref
Shasha Wang, Jing Lv, Shanshan Meng, Jianxin Tang & Liming Nie. (2020) Recent Advances in Nanotheranostics for Treat‐to‐Target of Rheumatoid Arthritis. Advanced Healthcare Materials 9:6, pages 1901541.
Crossref
Crossref
Michael CanigaHongshi YuHyun-Hee LeeMeiyao WangDavid WitterMichael SalmonPeter W. Fan. (2019) Estimation of Fraction Dissolved After Intratracheal Delivery of a Potent Janus Kinase Inhibitor, iJAK-001, with Low Solubility in Rat and Sheep: Impact of Preclinical PKPD on Inhaled Human Dose Projection. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32:5, pages 251-265.
Crossref
Crossref
Köhler, Günther, Kaudewitz & Lorenz. (2019) Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. Journal of Clinical Medicine 8:7, pages 938.
Crossref
Crossref
Francesca Musumeci, Chiara Greco, Ilaria Giacchello, Anna Lucia Fallacara, Munjed M. Ibrahim, Giancarlo Grossi, Chiara Brullo & Silvia Schenone. (2019) An Update on JAK Inhibitors. Current Medicinal Chemistry 26:10, pages 1806-1832.
Crossref
Crossref
Josef S. Smolen, Mark C. Genovese, Tsutomu Takeuchi, David L. Hyslop, William L. Macias, Terence Rooney, Lei Chen, Christina L. Dickson, Jennifer Riddle Camp, Tracy E. Cardillo, Taeko Ishii & Kevin L. Winthrop. (2019) Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. The Journal of Rheumatology 46:1, pages 7-18.
Crossref
Crossref
Qiangzhe Zhang, Diana Dehaini, Yue Zhang, Julia Zhou, Xiangyu Chen, Lifen Zhang, Ronnie H. Fang, Weiwei Gao & Liangfang Zhang. (2018) Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nature Nanotechnology 13:12, pages 1182-1190.
Crossref
Crossref
Roberto Giacomelli, Piero Ruscitti & Yehuda Shoenfeld. (2018) A comprehensive review on adult onset Still's disease. Journal of Autoimmunity 93, pages 24-36.
Crossref
Crossref
Zhi‑Peng Wu, Pei Zhang, Jian‑Zhong Bai, Yuan Liang, Jin‑Shan He & Jing‑Cheng Wang. (2018) Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease‑modifying anti‑rheumatic drugs: A meta‑analysis of randomized controlled trials. Experimental and Therapeutic Medicine.
Crossref
Crossref
Wassim Elyaman & Samia J. Khoury. (2016) Th9 cells in the pathogenesis of EAE and multiple sclerosis. Seminars in Immunopathology 39:1, pages 79-87.
Crossref
Crossref